Bain Capital Life Sciences Investors, LLC Nuvalent, Inc. Transaction History
Bain Capital Life Sciences Investors, LLC
- $370 Million
- Q4 2024
A detailed history of Bain Capital Life Sciences Investors, LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Bain Capital Life Sciences Investors, LLC holds 1,447,267 shares of NUVL stock, worth $113 Million. This represents 30.59% of its overall portfolio holdings.
Number of Shares
1,447,267
Previous 2,697,267
46.34%
Holding current value
$113 Million
Previous $276 Million
58.94%
% of portfolio
30.59%
Previous 49.52%
Shares
4 transactions
Others Institutions Holding NUVL
# of Institutions
234Shares Held
62.6MCall Options Held
834KPut Options Held
653K-
Deerfield Management Company, L.P. (Series C) New York, NY18MShares$1.4 Billion34.87% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY5.36MShares$418 Million16.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.5MShares$351 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.02MShares$236 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY2.62MShares$204 Million6.84% of portfolio
About Nuvalent, Inc.
- Ticker NUVL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,977,800
- Market Cap $3.35B
- Description
- Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...